CROI 2017 Abstract e-Book

Abstract eBook

General Information

ABSTRACT PROCESS

Scientific Categories A.Virology

B.Molecular Epidemiology and HIV/SIV Evolution C. Pathogenesis: Human Studies and Animal Models D.Host Immune Responses to Infection, Vaccines, and Immunotherapy E. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy F. Neuropathogenesis and CNS HIV Complications G.Clinical Pharmacology

General Information

H.Antiretroviral Therapy: Pre-Clinical and Randomized Trials I. Antiretroviral Therapy: Efficacy and Effectiveness Studies J. HIV Drug Resistance K.HIV Diagnostics L. Hepatitis Viruses and Liver Complications M. Malignancies N.Cardiovascular Complications of HIV Infection and Antiretroviral Therapy O.Other Complications of HIV Infection and Antiretroviral Therapy P. Tuberculosis and Other Opportunistic Infections Q.Maternal/Fetal HIV R.Pediatrics and Adolescents S. Epidemiology T. Prevention Interventions U.Prevention Scale-Up

V. Contraceptive and Reproductive Health inWomen W. Implementation and Scale-Up of Treatment and Care

X.Population and Cost Modeling Y. Emerging Viruses: Zika Virus Abstract Content Author names, institutions, abstract titles, and abstracts in the Program and Abstracts eBook are generally presented as submitted by the corresponding author. Abstract Review Process The PC and a panel of volunteer external reviewers reviewed approximately 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise. PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected). Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late- breaking nature of the work (versus just being a late submission).

2

CROI 2017